Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis
Open Access
- 31 May 2022
- Vol. 65 (7), 747-752
- https://doi.org/10.1111/myc.13469
Abstract
Background The broad-spectrum triazole isavuconazole is used for the treatment of invasive aspergillosis and mucormycosis. Data regarding human plasma concentrations in clinical routine of the drug are rare. Objectives Plasma concentrations of isavuconazole were determined in critically ill ICU patients while considering different patients' characteristics. Methods Retrospective analysis of isavuconazole plasma concentrations were obtained as part of routine therapeutic drug monitoring (TDM) of ICU patients with invasive aspergillosis or other fungal infections treated with isavuconazole. Plasma levels 0-4 h after last dosing were defined as peak levels (C-max), those 20-28 h after last dosing as trough levels (C-min). Results Overall, 223 isavuconazole levels of 41 patients were analysed, divided into 141 peak levels and 82 trough levels. The overall median C-max was 2.36 mu g/ml (mean 2.43 mu g/ml, range 0.41-7.79 mu g/ml) and the overall median C-min was 1.74 mu g/ml (mean 1.77 mu g/ml, range 0.24-4.96 mu g/ml). In total, 31.7% of the C-min values of the total cohort were below the plasma target concentrations of 1 mu g/ml, defined as EUCAST antifungal clinical breakpoint for Aspergillus fumigatus. Both peak and trough plasma levels of isavuconazole were significantly lower among patients with a body mass index (BMI) >= 25. In addition, a significant correlation was observed between isavuconazole trough levels and sepsis-related organ failure assessment (SOFA) score. Conclusions This study shows that isavuconazole plasma concentrations vary in critical ill ICU patients. Significantly lower isavuconazole levels were associated with elevated BMI and higher SOFA score indicating a need of isavuconazole TDM in this specific patient population.Keywords
This publication has 24 references indexed in Scilit:
- Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous FungiAntimicrobial Agents and Chemotherapy, 2017
- Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICsJournal of Antimicrobial Chemotherapy, 2017
- The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infectionsIntensive Care Medicine, 2017
- Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous FungiAntimicrobial Agents and Chemotherapy, 2016
- Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)Antimicrobial Agents and Chemotherapy, 2016
- Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysisThe Lancet Infectious Diseases, 2016
- Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialThe Lancet, 2015
- Isavuconazole: A New Broad-Spectrum Triazole Antifungal AgentClinical Infectious Diseases, 2015
- Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical MycologyJournal of Antimicrobial Chemotherapy, 2013
- The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failureIntensive Care Medicine, 1996